Studies related to Symptoms of Autism and N-Acetylcysteine

A Randomized Double Blind Placebo Controlled Clinical Trial Of N-Acetylcysteine Added To Risperidone For Treating Autistic Disorders

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 31
Sex Both Genders
Age Range 1-6, 7-12, 13-17
Notes for this study:
Eight weeks supplementation of NAC as adjuvant to risperidone therapy in children with autism was able to reduce irritability relative to placebo, but the other measured parameters (Lethargy and Social Withdrawal, Stereotypic Behavior, Hyperactivity, and Noncompliance) were not affected by treatment.

Full details on all 3 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.